奥扎格雷钠治疗冠心病心力衰竭的临床观察

The therapeutic effects of ozagrel sodium injection on chronic heart failure caused by coronary heart disease

目的观察奥扎格雷钠治疗冠心病慢性心力衰竭的疗效。方法冠心病慢性心力衰竭患者60例,随机分为对照组30例和治疗组30例。对照组给予常规治疗,治疗组在常规治疗的基础上,加0.9%氯化钠250m L+奥扎格雷钠80mg,静脉滴注,每日1次,连续10d。分别观察用药前及用药10d后两组患者临床症状、N-端脑利钠肽前体(NT-pro BNP)以及6min步行距离。结果治疗10d后,治疗组患者6min步行距离明显延长,与对照组比较差异有统计学意义(P<0.05)。对照组及治疗组N-端脑利钠肽前体水平较治疗前均降低(P<0.01或P<0.05),但治疗组血浆N-端脑利钠肽前体水平降低及心功能改善更显著(P<0.01)。结论奥扎格雷钠可显著改善冠心病慢性心力衰竭患者的临床心功能分级,治疗效果确切,安全性好。

Objective To investigate the therapeutic effect of ozagrel sodium on cardiac function in patients with chronic heart failure caused by coronary heart disease. Methods Total of 60 patients with chronic congestive heart failure caused by coronary heart disease who were admitted into Shandong University Qilu Hospital Qingdao area from Nov.2012 to Oct.2013. All patients were randomly divided into control group and treatment group consisting 30 cases respectively. The patients in control group were treated with routine curse while those in the treatment group were treated with routine curse combined with ozagrel sodium injection（ozagrel sodium injection, 80 mg, qd） for 10 days. After treatment for 10 days, the six minutes walk test was measured using the method proposed by Bittner. The serum level of NT-BNP was detected by enzyme linked immunoassay. Results After 10 days treated with ozagrel sodium injection, exercise tolerance of treatment group improved（P〈0.05）, while NT-BNP average level lowered, which were all significant（P〈0.01）. Conclusion Ozagrel sodium could improve heart function and exercise tolerance in patients with ischemic cardiomyopathy with a exact and safe therapeutic effect.